By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
EYSUVIS Drug Profile
Email this page to a colleague
Which patents cover Eysuvis, and what generic alternatives are available?
Eysuvis is a drug marketed by Kala Pharms Inc and is included in one NDA. There are eleven patents protecting this drug.
This drug has seventy patent family members in twelve countries.
The generic ingredient in EYSUVIS is loteprednol etabonate. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eysuvis
A generic version of EYSUVIS was approved as loteprednol etabonate by AKORN on April 17th, 2019.
Summary for EYSUVIS
| International Patents: | 70 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EYSUVIS |
| What excipients (inactive ingredients) are in EYSUVIS? | EYSUVIS excipients list |
| DailyMed Link: | EYSUVIS at DailyMed |
ATC Classes for EYSUVIS
US Patents and Regulatory Information for EYSUVIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Y | Get Started Free | |||
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Y | Get Started Free | |||
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EYSUVIS
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 6816064 | Get Started Free |
| World Intellectual Property Organization (WIPO) | 2013166385 | Get Started Free |
| Mexico | 2016005710 | Get Started Free |
| Japan | 6816065 | Get Started Free |
| China | 111700879 | Get Started Free |
| Australia | 2018201215 | Get Started Free |
| Japan | 2020050663 | Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
